Deubiquitinating enzymes at the crossroads of lipid metabolism and cancer by Gonidas, Christos et al.
Introduction
Metabolic rewiring has been recognized as a hallmark of
cancer [1]. Although the identification of changes in can-
cer cell metabolism date many decades back to the pio-
neering work of Otto Warburg in the beginning of the
twentieth century [2], the introduction of sophisticated
genetic and biochemical tools permitted the detailed dis-
section of cellular and molecular mechanisms underlying
the metabolic changes that accompany the development
of malignancies [3]. The identification and characterization
of metabolic steps that constitute major dependencies
for cancer cells dictated the development of successful
anticancer drugs and reemerges as an area of highly active
investigation [4]. In this report we focus on aspects of lipid
metabolism in cancer that are affected by deubiquitinat-
ing enzymes. This is an area that has attracted recent at-
tention and has the potential to reveal possibilities of ther-
apeutic interventions for cancer and metabolic diseases.
Following an overview of cancer associated alterations in
lipid metabolism we introduce a brief overview of protein
ubiquitination to focus in the end on specific deubiquiti-
nating enzymes that have roles in both cellular homeosta-
sis and lipid metabolism.
Lipid metabolism and cancer
Lipids play pleiotropic roles in animal cellular physiology.
Fatty acids are a major source of energy production under
aerobic conditions and in the form of glycerol esters they
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Deregulated lipid metabolism has been recognized as a critical alteration that supports the development and growth of
various types of tumors. Changes in lipid metabolism enable reprogramming of energetics and availability of synthetic in-
termediates and signaling mediators that can have pleiotropic effects in cellular physiology. The identification of critical fac-
tors that reshape lipid metabolism during oncogenesis can provide targets for the development of novel therapeutic
protocols. Enzymes are an attractive class of molecules for the development of therapeutic compounds. This review focuses
on deubiquitinating enzymes (DUBs) that have been implicated both in lipid and cellular homeostatic processes. In certain
cases, a causative link between the two processes is mediated by the deubiquitinating enzyme whereas in other cases we
present evidence that support a possible role for the DUB as the underlying linker of lipid content and cell growth deregu-
lation. Collectively, our report highlights critical nodes of deubiquitination-dependent metabolic and growth regulatory
processes that can be interrogated further for a detailed understanding of cancer promoting mechanisms and therapeutic
exploitation. 
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Deubiquitinating enzymes at the crossroads 
of lipid metabolism and cancer
provide an efficient means for energy storage. Phospho-
lipids and sphingolipids are fundamental components of
membranes. Finally, various types of lipids play critical
roles in signal transduction processes that orchestrate re-
sponses to extracellular stimuli. The broad range of struc-
tural and functional effects that are mediated by lipids ex-
plain the deregulation of multiple aspects of their home-
ostasis in cancer. Malignant cells have increased demands
for membrane synthesis and energy due to their enhan -
ced proliferation rates [5]. Therefore, it comes as no sur-
prise that they reorganize several processes associated
with the availability and use of different types of lipids [6].
These processes include enhanced fatty acid synthesis
and modifications in fatty acid liberation from endoge-
nous sources, increased uptake of fatty acids from the en-
vironment, increased fatty acid oxidation and deregulation
of cholesterol metabolism.
Specific changes in gene expression and protein func-
tion underlie the metabolic changes associated with lipid
homeostasis deregulation in cancer. Fatty acid synthase
which is the principal fatty acid biosynthetic enzyme is
upregulated in various types of cancer [7, 8]. In addition,
inhibition of ATP citrate lyase and acetyl-coA carboxylases
that catalyze early steps in fatty acid synthesis have tu-
moricidal effects [9]. Similar effects have been associated
with the use of statins that inhibit cholesterol biosynthesis
[10]. Notably, aberrant activation of the transcription fac-
tors SREBP1 and SREBP2, which orchestrate fatty acid and
cholesterol biosynthesis, has been observed in different
types of cancer [11, 12, 13]. These findings highlight the
importance of de novo fatty acid and cholesterol biosyn-
thesis for the growth of cancer cells. In addition to de novo
biosynthesis of lipids, cancer cells acquire survival benefits
if they can facilitate import of lipids from their microen-
vironment. This is based on the enhanced expression of
molecules implicated in lipid binding and import and in-
clude CD36, fatty acid binding proteins and proteins in-
volved in lipoprotein import and processing [14, 15, 16].
Fatty acids constitute a rich energy source that is alterna-
tive to glucose. Gene expression mediated enhancement
of processes that mediate fatty acid oxidation in mito-
chondria has been observed in breast cancers, pancreatic
cancers and glioblastomas [17, 18, 19, 20]. In addition to
energy production, fatty acid oxidation can support the
antioxidant armamentarium of the cell by increasing the
levels of NADPH [21]. Nevertheless, unregulated accumu-
lation of lipids can lead to toxic effects and cancer cells
develop mechanisms of lipid storage and metabolism re-
organization to avoid lipotoxicity effects. These include
the formation of lipid droplets and the activation of a spe-
cialized autophagy mechanism for lipids called lipophagy
[22, 23]. In addition, enzymes involved in lipolysis are reg-
ulated appropriately to establish fatty acid homeostasis
[24]. Finally, cancer cells must balance the levels of satu-
rated and unsaturated fatty acids depending on the en-
vironmental conditions in which they grow [25]. Polyun-
saturated fatty acids can undergo peroxidation by reactive
oxygen species and lead to cell death by an iron-depen-
dent mechanism called ferroptosis. Cells with polyunsat-
urated fatty acids in membranes are more vulnerable to
ferroptosis and they develop mechanisms to reduce mem-
brane polyunsaturated fatty acid content. These include
de novo lipogenesis and redistribution of polyunsaturated
fatty acids between phospholipids and triacyl glycerols
[26, 27]. On the other hand, increased levels of saturated
fatty acids in membranes can have toxic effects. In order
to balance this situation, cancer cells rely on elevated lev-
els of fatty acid desaturating enzymes such as stearoyl-
CoA desaturase 1 to increase the levels of unsaturated fat-
ty acids [28, 29]. In summary, lipid metabolism reprogram-
ing in cancer is pleiotropic to allow for the optimal adap-
tation, survival, growth, and dissemination of cancer cells
in their changing microenvironment. Identifying mole cu -
les that mediate such a metabolic plasticity is of para -
mount importance for the development of effective ther-
apeutic approaches. 
Protein ubiquitination deubiquitination and
cancer
Ubiquitination constitutes an evolutionarily conserved
posttranslational modification of proteins that mediates
the regulation of a broad range of processes that are tight-
ly associated with cellular homeostatic mechanisms (re-
viewed in [30]). Typically, it involves the attachment of
ubiquitin, a 76-amino acid protein, to the side chain of a
lysine residue on the target protein. The attachment is
mediated by an isopeptide bond between the ubiquitin
carboxyl terminal group and the e-amino group of the ly-
sine residue. Proteins can be modified by monoubiquiti-
nation (attachment of one ubiquitin moiety) or polyubiq-
uitination (attachment of multiple linked ubiquitin moi-
eties) to one or multiple lysine residues. Polyubiquitin
chains can be formed by conjugating the carboxyl termi-
nus of one ubiquitin to one of the seven lysine residues
(termed KX-linked chains, where X is the respective lysine
residue number) or the amino terminal methionine
(termed M1-linked chains) of the neighboring ubiquitin
molecule. Structurally and functionally distinct types of
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polyubiquitin chains can be formed depending on which
ubiquitin lysine residue is used to form the isopeptide
linkage with the neighboring ubiquitin molecule. For ex-
ample, K48-linked polyubiquitin chains mediate protea-
some-dependent protein degradation whereas K63- and
M1-linked polyubiquitin chains are used in the assembly
of signaling complexes. The repertoire of ubiquitin-based
recognition codes is further expanded by the formation
of mixed-linkage chains, conjugation of ubiquitin with
ubiquitin-like molecules and ubiquitin modifications such
as phosphorylation and acetylation. 
Protein ubiquitination is an enzymatic process that is
typically carried out by the cooperation of a ubiquitin ac-
tivating enzyme (E1), a ubiquitin conjugating enzyme (E2)
and a ubiquitin ligase (E3) [31]. E3s usually confer the
specificity of target selection, thus they represent the
largest group of cooperating enzymes for protein ubiq-
uitination. Importantly, protein ubiquitination can be re-
versed by proteolytic enzymes known as deubiquitinating
enzymes (DUBs), which can hydrolyze the isopeptide
bond that links ubiquitin moieties to each other and the
target protein [32]. They fall in different classes based on
the structural characteristics of their ubiquitin-protease
domain and they can be selective or specific towards dif-
ferent types of polyubiquitin chains. Protein ubiquitination
and deubiquitination are tightly regulated in accordance
with the broad range of cellular functions that mediate
and control. Interestingly, multiple enzymes involved in
protein ubiquitination have been implicated in cellular
homeostatic processes including cancer-preventing
checkpoint bypass [33]. Frequently, such checkpoints in-
volve the rewiring of metabolic processes that can fuel
the growth of cancer cells. Deubiquitinating enzymes that
have been associated with cancer development and lipid
metabolism will be the focus of the following sections.
DUBs implicated in cellular homeostasis and
lipid metabolism 
Gene expression and genetic analyses have highlighted
the association or involvement of several DUBs in tumor
development [34]. Oncogenic and tumor suppressing ac-
tivities have been ascribed to these enzymes but the full
spectrum of molecular mechanisms that underlie these
activities is incompletely understood in many cases.
A20, which is also known as TNFAIP3, is a ubiquitin-
editing enzyme encoded by a gene that is frequently in-
activated by mutations in B-cell lymphomas including
multiple myeloma, diffuse large B cell lymphoma, Hod g -
kin’s lymphoma, and follicular lymphoma [35]. Tumor pro-
moting activities have been ascribed to A20 by virtue of
its upregulation in glioblastoma and certain types of
breast cancer. Interestingly, A20 is a critical regulator of
lipid homeostasis in hepatocytes and its genetic inacti-
vation exacerbates non-alcoholic steatohepatitis, a con-
dition that can lead to hepatocellular carcinoma [36]. Con-
sistent with these findings is the suppression of free fatty
acid-mediated triglyceride accumulation in HepG2 cells
by A20 overexpression, whereas its downregulation had
the opposite effect [37]. A20 contains an amino terminal
deubiquitinating domain and seven carboxyl terminal
zinc-finger domains that include an E3 ligase domain. It
has a well-established inhibitory activity towards NF-kap-
paB activation which plays a central role in its anti-inflam-
matory function. Furthermore, A20 has a profound anti-
apoptotic role which may underlie its tumor promoting
properties. Its NF-kappaB inhibitory activity has been
linked to its ability to hydrolyze K63-inked polyubiquitin
chains from various NF-kappaB activation mediators such
as RIPK1 or NEMO, followed at least in some cases by their
degradative ubiquitination by its E3 ligase activity. Fur-
thermore, the seventh zinc finger domain of A20 can bind
linear polyubiquitin chains and modulate their stability
and accessibility by other proteins to regulate NF-kappaB
activation by TNF. The anti-inflammatory and death-pre-
venting activities of A20 have been associated with con-
ditions that can promote oncogenesis. Interestingly, its
effects on lipid homeostasis have recently emerged as an
additional factor that can promote tumorigenesis partic-
ularly in the liver. The ability of A20 to prevent lipid accu-
mulation in hepatocytes has been linked to its ability to
deubiquitinate and inactivate the ASK1 kinase and limit
the downstream activation of p38 and JNK1/2 as well as
its ability to promote fatty acid oxidation and decrease
fatty acid and cholesterol uptake involving among other
mechanisms the induction of PPARalpha levels [36]. It
would be interesting to investigate whether A20 affects
lipid homeostasis in other cell types in a manner that af-
fects their growth and survival.
The tumor suppressor CYLD is a deubiquitinating en-
zyme that was originally identified as a gene mutated in
familial cylindromatosis and its loss in various tumor types
results in enhanced cell survival or cell proliferation (re-
viewed in [38]). The human CYLD protein consists of 956
amino acids and contains three cytoskeletal-associated
protein-glycine-conserved (CAP-Gly) repeats, two con-
served proline-rich segments, and a carboxyl terminal deu-
biquitinating domain (reviewed in [39]). The two amino
terminal CAP-Gly domains mediate the interaction of CYLD
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with microtubules, which affects microtubule dynamics.
Depending on the cell type and stimulus, CYLD can inhibit
several growth and antiapoptotic signaling pathways that
include the NF-kappaB, JNK and p38 pathways (reviewed
in [40]). The inhibition of these pathways by CYLD is me-
diated by the deubiquitination of critical signaling mole-
cules and the apparent disruption of multisubunit com-
plexes that are assembled on K63- and M1-linked polyu-
biquitin chains. Targets of CYLD that play a critical role in
the inhibition of the aforementioned pathways include
the kinases RIPK1 and TAK1, the E3-ubiquitin ligases TRAF2
and TRAF6 and the transcription factor Bcl3 (reviewed in
[40]. CYLD expression can be modulated by transcription
regulation as well as via posttranslational modifications.
Interestingly, several pieces of evidence have indicated a
role for CYLD in lipid homeostasis with direct implications
for cellular homeostasis. CYLD downregulation has been
associated with steatosis and non-alcoholic steatohepatitis
in humans [41]. Furthermore, genetic inactivation of the
CYLD gene in mouse hepatocytes enhances lipid accumu-
lation upon high-fat diet conditions whereas overexpres-
sion of CYLD in hepatocytes ameliorates the effects of high
fat diet. The detrimental effects of CYLD-deficiency in he-
patocytes are also associated with exacerbation of inflam-
mation. The protective effect of CYLD towards non-alco-
holic steatohepatitis has been linked to its ability to inhibit
hyperactivation of the TAK1 kinase and its downstream ef-
fector JNK [41, 42]. Based on these findings it has been
suggested that upregulation of CYLD may have beneficial
effects for non-alcoholic steatohepatitis. Interestingly pi-
oglitazone, which is a PPARgamma activator is recom-
mended for the treatment of a subset of non-alcoholic
steatohepatitis patients and we have demonstrated that
PPARgamma activation can induce the expression of CYLD
mRNA and protein [43]. It is conceivable that the beneficial
effect of pioglitazone in non-alcoholic steatohepatitis pa-
tients may be mediated at least partly through the induc-
tion of CYLD. Finally, it is worth noting that the effects of
CYLD on lipid homeostasis may be evolutionarily con-
served since downregulation of the Drosophila melano -
gaster CYLD ortholog resulted in altered fat body morphol-
ogy, increased triglyceride levels and increased survival
under starvation conditions [44]. 
BAP1 is a deubiquitinating enzyme with broad tumor
suppressing activities that include mesothelioma, renal
cell carcinoma, uveal melanoma and hepatocellular carci-
noma [45]. BAP1 participates in multiple chromatin -asso-
ciated complexes and plays a critical role in the regulation
of gene expression, DNA replication and repair by inducing
the deubiquitination of specific targets. A notable BAP1
target is histone H2A, the deubiquitination of which is in-
volved in the control of gene expression.  Liver specific in-
activation of the BAP1 gene resulted in hypercholes-
terolemia and marked reduction of lipid accumulation in
the liver [46]. These phenotypic effects were associated
with elevated levels of enzymes involved in cholesterol
biosynthesis and downregulation of genes involved in lipid
uptake and/or storage. Furthermore, inactivation of BAP1
by cytoplasmic retention, which is mediated by its ubiq-
uitination, promotes adipocyte differentiation [47]. The
link between the tumor suppressing and metabolic regu-
latory activities of BAP1 is conceivable but additional stud-
ies are required to firmly establish such an association.
Several DUBs with predominantly oncogenic activities
have been associated with lipid homeostatic mechanisms.
The oncogenic activities of USP2a have been primarily
linked to its ability to deubiquitinate and stabilize growth
regulatory proteins including cyclins, MDM2 and beta-
catenin [48]. Interestingly, USP2a can deubiquitinate and
stabilize fatty acid synthase to promote fatty acid synthesis
which can presumably fuel the growth of tumor cells [49-
51]. Consistent with this notion is the ability of the onco-
genic and prolipogenic activity of the Akt kinase to induce
the expression of USP2a in hepatocellular carcinoma [51].
Furthermore, the lipogenic ability of USP2a to deubiqui-
tinate and stabilize fatty acid synthase was associated with
the growth transforming properties of Epstein-Barr virus
and its principal oncoprotein LMP1 in B cells [52]. USP7
promotes cell survival and proliferation by various mech-
anisms involving the deubiquitination and stabilization
of critical regulators. Its role in stabilizing preferentially
the p53 E3 ligase MDM2 is well established and prompted
he development of USP7 inhibitors for the treatment of
relevant tumors. USP7 enhances insulin sensitivity by deu-
biquitinating and stabilizing PPARgamma and IRS1 [53,
54]. The potential effects of these metabolic reprogram-
ming activities on the promotion of tumorigenesis remain
to be established.  USP14 expression has been correlated
with the development or progression of several malig-
nancies including prostate cancer, hepatocellular carci-
nomas, lung cancers and multiple myeloma (reviewed in
[55]). Notable direct or indirect targets of USP14 are the
androgen receptor and beta-catenin. Interestingly, USP14
deubiquitinates and stabilizes the fatty acid synthase to
promote de novo lipogenesis which may promote the
growth tumor cells at least in some cases [56]. Clearly, fur-
ther studies are need to establish the broader significance
of lipid metabolism regulation by USP14 and its tumor
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promoting activities. USP18 has cell growth promoting
effects by positively regulating EGF receptor expression
(reviewed in [57]). Notably, USP18 was downregulated in
the livers of non-alcoholic steatohepatitis patients and
mice treated with high fat diet [58]. Furthermore, its ex-
ogenous expression in hepatocytes was shown to protect
mice from high fat diet induced liver steatosis whereas its
genetic inactivation exacerbated hepatic steatosis. The
protective effects of USP18 towards high fat diet induced
liver steatosis were associated with its ability to inhibit hy-
peractivation of TAK1, similarly to the function of CYLD.
These findings highlight the critical role of TAK1 activity
regulation for the metabolic homeostasis of hepatocytes.
USP34 is a deubiqutinating enzyme that can promote cell
growth by positively regulating Wnt signaling [59]. USP34
plays an important role in liver homeostasis by deubiqui-
tinating and stabilizing gp78, a well-established regulator
of lipid biogenesis in the liver [60]. Given the fact that ge-
netic inactivation of gp78 causes obesity and non-alco-
holic steatohepatitis in mice it would be important to ex-
plore the potential involvement of USP34 in steatohep-
atitis cases and associated pathologies in humans. 
Conclusion
Deubiquitination has emerged as a critical posttransla-
tional regulatory mechanism for a broad spectrum of cel-
lular processes with important pathophysiological roles
including cell and tissue homeostasis and its disruption
in tumorigenesis. Many efforts during the recent years
have been focusing on understanding the metabolic de-
viations that fuel the development of cancer with the ul-
timate goal to design innovative and effective therapeutic
schemes. In this review, functional relations between the
tumor inhibiting or promoting role of DUBs and their in-
volvement in lipid metabolism have been highlighted to
reveal novel concepts of combinatorial therapeutic inter-
ventions that may be beneficial in a clinical setting. To-
wards this goal, DUBs with oncogenic activities could be
targeted with small molecule inhibitors [61] whereas the
downregulation of DUBs with tumor suppressing activity
could be reversed by molecules that target transcriptional
or posttranscriptional regulatory mechanisms. These in-
terventions could be combined with drugs that modulate
lipid homeostasis and standard chemotherapeutic agents.
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